Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Dominari Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $52.92 Mil. Dominari Holdings's Total Assets for the quarter that ended in Dec. 2023 was $57.56 Mil.
Therefore, Dominari Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.92.
The historical rank and industry rank for Dominari Holdings's Equity-to-Asset or its related term are showing as below:
DOMH'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46 Med: 0.92 Max: 0.99
Current: 0.92
During the past 13 years, the highest Equity to Asset Ratio of Dominari Holdings was 0.99. The lowest was 0.46. And the median was 0.92.
DOMH's Equity-to-Asset is ranked better than 89.83% of 1564
companies
in the Biotechnology industry
Industry Median: 0.66
vs DOMH: 0.92
Dominari Holdings Equity-to-Asset Historical Data
The historical data trend for Dominari Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dominari Holdings's Equity-to-Asset
For the Biotechnology subindustry, Dominari Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dominari Holdings's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dominari Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Dominari Holdings's Equity-to-Asset falls into.
Dominari Holdings Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Dominari Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Dominari Holdings Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Dominari Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Dominari Holdings (Dominari Holdings) Business Description
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DOMH has been successfully added to your 